The World Health Organization (WHO) has issued a position paper for GSK's malaria vaccine candidate RTS,S (also known as MosquirixTM).
The WHO position paper recommends large-scale pilot implementations of RTS,S. The recommendation confirms the advice provided last fall by the WHO Strategic Advisory Group of Experts on Immunization (SAGE) and Malaria Policy Advisory Committee (MPAC).
Published in the Weekly Epidemiological Record (WER) on January 29, the WHO position paper “…recommends that the pilot implementations use the 4-dose schedule of the RTS,S/AS01 vaccine in 3–5 distinct epidemiological settings in sub-Saharan Africa, at subnational level, covering moderate-to-high transmission settings,” with three doses administered to children between 5 months and 9 months of age, followed by a fourth dose 15–18 months later.
WHO further recommends that the pilots involve sufficiently large populations to assess, among other things, (1) the feasibility of providing all four doses of RTS,S to the target age group through existing health services; (2) the impact of RTS,S on child mortality; and (3) evidence of any causal relationship between RTS,S and either meningitis or cerebral malaria, in the context of surveillance of adverse events; as well as the compilation of evidence on the functioning of country immunization programs and the use of currently recommended malaria control measures.
Visit the WHO website to read the position paper.